CJC-1295 avec DAC
5 MGCJC-1295 DAC — long-acting GHRH(1-29) analog for research
Studied therapeutic interests:
CJC-1295 (also called DAC:GRF — Drug Affinity Complex: Growth Hormone-Releasing Factor) is a synthetic analog of human GHRH(1-29) (Growth Hormone-Releasing Hormone) modified to extend its plasma half-life. Developed by ConjuChem, this research peptide incorporates four strategic substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) conferring resistance to the enzymatic degradation common to native GHRH.
The DAC (Drug Affinity Complex) version contains an additional maleimidopropionic acid group that covalently binds albumin in vivo, dramatically extending the half-life from a few minutes (native GHRH) to approximately 6-8 days. This pharmacokinetic property makes it a valuable research tool for studies requiring prolonged GHRH pathway stimulation.
Preclinical studies have extensively documented effects on somatotroph pituitary cells and the GH/IGF-1 axis. CJC-1295 binds the GHRH-R receptor with high affinity (Kd ≈ 0.3 nM) and stimulates cAMP accumulation and GH secretion in a dose-dependent manner. Studies on somatotroph cell lines (e.g. MtT-S, GH3) and primary pituitary cultures are classical models.
At OSMOSE Research, CJC-1295 is supplied as a lyophilized powder with HPLC purity ≥ 99.2%. Manufactured in Europe under GMP standards, this research peptide is delivered to France, Belgium, Switzerland, Luxembourg and worldwide internationally with insulated packaging.
- Preclinical research on the somatotroph axis (GH/IGF-1)
- Studies on somatotroph pituitary cells
- Pulsatile vs sustained GH secretion research
- Comparative pharmacokinetic studies (DAC vs without DAC)
- In vitro models of GHRH-R signaling
- Preclinical muscle repair research
- Studies on bone biogenesis and IGF-1
- Comparative research on GHRH analogs
CJC-1295 is one of the most studied research peptides in endocrinology for its effects on the somatotroph axis. The foundational work of Teichman et al. (2006) demonstrated a plasma half-life of approximately 8 days and a dose-dependent elevation of IGF-1 levels in preclinical models. Research topics include: pharmacodynamic comparison between CJC-1295 with and without DAC (Mod GRF 1-29), cAMP/PKA signaling in somatotrophs, regulation of GH pulsatility, and interactions with the somatostatinergic system. Studies on non-human primate models show IGF-1 elevation persisting 6-11 days after a single dose, relevant for long-term signaling research.
- HPLC purity ≥ 99.2% verified by RP-HPLC
- Molecular mass certified by ESI-MS
- Endotoxin test < 0.5 EU/mg by LAL
- Sterility validation
Frequently asked questions
CJC-1295 DAC contains a maleimidopropionic acid group that covalently binds albumin, dramatically extending its half-life to ~8 days. The version without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes, allowing more physiological GH pulsatility. The choice depends on the research objective: prolonged signaling (with DAC) vs pulsatile (without DAC).
CJC-1295 binds the GHRH-R receptor with high affinity (Kd ≈ 0.3 nM) and activates the Gs-protein pathway, stimulating adenylyl cyclase and cAMP production. This signaling cascade leads to GH1 gene transcription and growth-hormone secretion by somatotroph cells.
The classical models are somatotroph cell lines MtT-S and GH3 (rat tumor-derived), primary pituitary cultures and recombinant HEK-293 cells expressing human GHRH-R. These models allow study of cAMP signaling, GH secretion and receptor desensitization kinetics.
The four substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) confer resistance to degradation by DPP-IV (dipeptidyl peptidase IV), which rapidly cleaves native GHRH, and to other enzymatic degradation pathways. These modifications preserve full affinity for GHRH-R while considerably extending plasma half-life.
Lyophilized CJC-1295 dissolves in bacteriostatic water or sterile saline. Typical in vitro concentrations are 1 nM to 100 nM for binding studies and cAMP activation. Once reconstituted, the solution remains stable for 28 days at 4 °C.
No. CJC-1295 is an experimental peptide intended exclusively for in vitro research. It has no MA (ANSM, EMA, FDA) for therapeutic use and cannot be administered to humans outside of clinical research protocols.
Preclinical studies in non-human primates show sustained IGF-1 elevation 6-11 days after a single dose of CJC-1295 DAC, proportional to dose. This prolonged elevation is relevant for long-term studies of the somatotroph axis, distinguishing it from short-acting GHRH analogs.
Main research precautions include: avoiding repeated freeze-thaw cycles (stability loss), verifying DAC presence by mass spectrometry (the DAC group characteristically increases molecular weight), and considering GHRH-R desensitization kinetics in long-duration protocols.
Each CJC-1295 batch undergoes RP-HPLC analysis with UV detection at 220 nm verifying purity ≥ 99.2%, molecular mass by ESI-MS confirming integrity (3367.7 g/mol with DAC), and endotoxin test by LAL. These analyses are included in the certificate of analysis (CoA).
CJC-1295 allows in-depth study of GHRH pathway: cAMP/PKA activation, CREB phosphorylation, GH1 gene transcription, GH secretion and possible GHRH-R desensitization. Comparative studies with other GHRH analogs (sermorelin, tesamorelin) enrich structure-activity understanding.
Complete your research
Often ordered together by our researchers
All products on this page are intended exclusively for in vitro scientific research and laboratory use. They are not intended for human or animal consumption, nor for diagnostic or therapeutic use. The buyer assumes full responsibility for compliance with applicable local regulations.